BPC November 13 update

Myovant MYOV shares rally on Urovant UROV buyout; ​Kazia KZIA heads higher ahead of data next week

Price and Volume Movers

Kazia Therapeutics Limited (NASDAQ:KZIA) shares closed up 30% to $8.98. The company is due to present further data from its trial of Paxalisib (GDC-0084) in patients with Glioblastoma at the Society for Neuro-Oncology meeting on November 20, 2020. Data from its Phase 1 trial in patients in newly diagnosed diffuse intrinsic pontine glioma (DIPG) will also be presented.

Urovant Sciences (NASDAQ:UROV) shares closed up 93% to $16.02 on news released late-Thursday that Sumitovant Biopharma will acquire the outstanding shares of Urovant not already owned by Sumitovant at a price of $16.25 per share in cash.

Myovant Sciences Ltd. (NASDAQ:MYOV) made a positive move in sympathy to the Urovant news, closing up 16% to $19.83, with investors anticipating a similar result for Myovant with Sumitovant being the majority shareholder of both Urovant and Myovant.

PLx Pharma Inc. (NASDAQ: PLXP) shares closed up 17% to $4.30. The company announced that its third quarter financial results call has been rescheduled from Friday, November 16 to Monday, November 16, 2020. No reason was provided for the change.


Major price movers (stocks priced > $1.00, volume > 50k listed on NASDAQ/NYSE):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume:


Navidea Biopharmaceuticals, Inc. (NAVB): $2.76; +23%.

Aerpio Pharmaceuticals, Inc. (ARPO): $1.68; +21%.

Summit Therapeutics Inc. (SMMT): $4.85; +18%.

Larimar Therapeutics, Inc. (LRMR): $22.50; +17%.

Aligos Therapeutics, Inc. (ALGS): $19.70; +16%.


Cassava Sciences, Inc. (SAVA): $8.37; -25%.

Liminal BioSciences Inc. (LMNL): $3.68; -11%.

Akers Biosciences, Inc. (AKER): $2.01; -9%.

Oramed Pharmaceuticals Inc. (ORMP): $2.54; -8%.

Adial Pharmaceuticals, Inc. (ADIL): $1.84; -8%.

Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst Market Cap

ATOS – Atossa Therapeutics Inc.
Mammographic breast density (MBD)

Phase 2 Phase 2 initiation due in 2020 (Sweden).
$18.5 million

BBIO – BridgeBio Pharma Inc.
Solid tumors

Phase 1 Phase 1 initiation of dosing announced November 13, 2020.
$6.2 billion

BPTH – Bio-Path Holdings Inc.
Solid tumors

Phase 1 Phase 1 trial to commence in 4Q 2020.
$16.1 million

CFRX – ContraFect Corporation
CF-301 exebacase
Serious infections caused byStaph aureus including MRSA

Phase 3 Phase 3 initiation of dosing announced January 10, 2020. Continues to enroll as of November 2020.
$175.8 million

CMPI – Checkmate Pharmaceuticals Inc.
CMP-001 and pembrolizumab
Head and neck squamous cell carcinoma (HNSCC)

Phase 2 Phase 2 trial planned late 2020/early 2021.
$261.4 million

HRTX – Heron Therapeutics Inc.
Post operative pain

NDA Filing CRL announced June 29, 2020. NDA resubmission announced November 13, 2020.
$1.6 billion

MIST – Milestone Pharmaceuticals Inc.
Etripamil - RAPID
Paroxysmal supraventricular tachycardia (PSVT)

Phase 3 Phase 3 commencement of enrollment announced November 18, 2020. Data due late 2021/early 2022.
$199.8 million

MRK – Merck & Company Inc. (new)
Keytruda KN-355
Triple negative breast cancer (TNBC)

Approved FDA Approval announced November 13, 2020.
$203.4 billion

PMVP – PMV Pharmaceuticals Inc.
Solid tumors

Phase 1/2 Phase 1/2 dosing of first patient announced November 23, 2020.
$1.6 billion

PRVL – Prevail Therapeutics Inc.
Parkinson’s disease with GBA1 mutation

Phase 1/2 Phase 1/2 biomarker and safety analysis due mid-2021.
$351.7 million

PRVL – Prevail Therapeutics Inc.
Frontotemporal Dementia Patients with GRN Mutations

Phase 1/2 Phase 1/2 trial to be initiated 4Q 2020. Biomarker and safety analysis due 2021.
$351.7 million

QLGN – Qualigen Therapeutics Inc.

Phase 1/2 Phase 1/2 trial to commence 1H 2021.
$80.3 million

STTK – Shattuck Labs Inc.
Ovarian Cancer

Phase 1 Phase 1 dose escalation data due 2H 2021.
$1.5 billion

VCNX – Vaccinex Inc.
Pepinemab and Keytruda
Head and Neck Squamous Cell Carcinoma

Phase 1/2 Phase 1/2 trial to commence 1H 2021.
$47.2 million